key: cord-0774508-2osqpvcm authors: Takazono, Takahiro; Mukae, Hiroshi; Izumikawa, Koichi; Hasegawa, Naoki; Yokoyama, Akihito title: COVID-19 associated pulmonary aspergillosis: a nationwide survey by the Japanese Respiratory Society date: 2021-08-26 journal: ERJ Open Res DOI: 10.1183/23120541.00402-2021 sha: ff9280f6bed1820e492823ca05d88fb9ab61a379 doc_id: 774508 cord_uid: 2osqpvcm The pandemic of coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread worldwide and resulted in more than 3.5 million people deaths as of June 2021 [1]. Respiratory viruses, such as the influenza virus, cause direct damage to the airway epithelium, enabling Aspergillus to invade airway tissues. SARS-CoV-2 infection can also increase the risk of Aspergillus superinfection, i.e., the so-called COVID-19 associated pulmonary aspergillosis (CAPA), in severe COVID-19 patients [2]. CAPA has become a serious concern worldwide for the management of severe COVID-19 [2]. Several studies have reported a high incidence of CAPA and associated mortality rates in critical COVID-19 patients [3–12]. However, these reports were from limited facilities in the United States (US) or European countries, and epidemiological data from other regions of the world are limited. Therefore, we conducted a nationwide internet questionnaire surveillance study in Japan to obtain large-scale epidemiological data. The pandemic of coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread worldwide and resulted in more than 3.5 million people deaths as of June 2021 [1] . Respiratory viruses, such as the influenza virus, cause direct damage to the airway epithelium, enabling Aspergillus to invade airway tissues. SARS-CoV-2 infection can also increase the risk of Aspergillus superinfection, i.e., the so-called COVID-19 associated pulmonary aspergillosis (CAPA), in severe COVID-19 patients [2] . CAPA has become a serious concern worldwide for the management of severe COVID-19 [2] . Several studies have reported a high incidence of CAPA and associated mortality rates in critical COVID-19 patients [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . However, these reports were from limited facilities in the United States (US) or European countries, and epidemiological data from other regions of the world are limited. Therefore, we conducted a nationwide internet questionnaire surveillance study in Japan to obtain largescale epidemiological data. An internet questionnaire survey was conducted with the chief physicians of respiratory disease departments of 715 Japanese Respiratory Society certified hospitals using Google Form between January 28, 2021 and February 28, 2021. The questionnaire included the total number of COVID-19 cases diagnosed based on reverse transcription-polymerase chain reaction testing and incidence of CAPA in each hospital from the beginning of the COVID-19 pandemic to January 27, 2021. Information of CAPA patients such as age groups, underlying diseases, the severity of COVID-19 according to the National Institute of Health treatment guidelines [13] , evidence for the diagnosis of CAPA, treatment, and their outcomes was collected. Informed written consent was not required because the study utilised de-identified data of patients and was approved by the Japanese Respiratory Society. In this study, we performed an online nationwide questionnaire survey and found that the incidence rate of CAPA in critical COVID-19 cases was extremely low (0.54%) compared with those previously reported, as summarised in Table 1 . The study subjects in these reports were ICU managed or critical COVID-19 patients. The incidence rates were 3.3 to 35% in the US and European countries (Table 1) . Obtaining mycological evidence from COVID-19 patients is challenging because diagnostic bronchoscopy could increase the exposure risk of dispersed aerosols to healthcare workers. Therefore, it was difficult to acquire mycological evidence of Aspergillus infection. Serological diagnostic tests, such as Aspergillus GM and BDG were useful in this situation. Data from the National Mycology Reference Laboratory, United Kingdom showed a relatively higher positivity rate (80%) for CAPA through the BDG test than through the GM antigen test (33%) [14] . It is unlikely that many patients with CAPA were overlooked in Japan for the following three reasons. First, data were obtained from mostly tertiary medical centres, including the mortality rates/100,000 population of COVID-19 in Japan are similar to those of the US and lower than those of European countries [15] . Japan has experienced three waves of the COVID-19 pandemic; the second and third waves were much larger than the first one. Use of corticosteroids, mainly dexamethasone, for COVID-19 patients with hypoxia was also recommended since the second wave had hit the country; hence, it is unlikely that the rate of steroid use was lower in Japan than in other countries. The previous studies were active surveillance studies with each specific diagnostic criterion and could be more accurate compared to our surveillance though the sample sizes were small. Therefore, the reason for the large difference in the incidence rate of CAPA among COVID-19 patients in our study compared with that among those in the United States and European countries might be the difference in study designs. However, recent meta-analysis of COVID-19 autopsy cases studies mainly from US or European countries showed the very low incidence of CAPA as 8/677 (1.18%) [16] . Therefore, the possibility that clinical criteria used in initial studies might involve over diagnosis cases due to colonization of Aspergillus spp. The other reason for the high incidence rate of CAPA could be due to publication bias. The strong point of this study is that we could perform a large-scale, nationwide survey. Our study has some limitations. The available data were limited to the nature of the questionnaire-based study. The diagnosis of CAPA was based on the judgement of each physician, but not based on defined diagnostic criteria. The information such as previous Aspergillus infections or colonization were not collected in CAPA patients. In conclusion, our results suggest that the incidence of CAPA in Japan may not be as high as expected from other studies. However, the diagnosis of CAPA is challenging, a large-scale prospective surveillance studies based on international guidelines are warranted to investigate the epidemiology of CAPA. World Health Organization Coronavirus (COVID-19 Infectious Diseases Working Party of the German Society for H, Medical O, Association of Medical M, Infectious Disease C. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance COVID-19 Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19) Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19 Shimabukuro-Vornhagen A. COVID-19 associated pulmonary aspergillosis COVID-19-associated Pulmonary Aspergillosis COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity Risk Factors for Invasive Pulmonary Aspergillosis in Critically Ill Patients With Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study COVID-19-associated invasive pulmonary aspergillosis NIH COVID-19 treatment guidelines COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory Invasive mould disease in fatal COVID-19: a systematic review of autopsies We acknowledge the members of the COVID-19 expert opinion working group of the Japanese Respiratory Society for their support in this study. This study was not supported by any specific grant. The authors have no conflicts of interest to declare.